Axial Biotech snares $6M tranche of venture funding

Johnson & Johnson Development Corporation along with vSpring Capital and Ohio Biotech Group have stepped in to provide a $6 million tranche for Axial Biotech's second round of venture capital. Axial is advancing new technology in molecular diagnostics and motion preserving to develop a genetic prognostic test for Adolescent Idiopathic Scoliosis. Axial says it has met several scientific milestones in its work on the test.

- see this release for more

ALSO: EnGene, which is developing a treatment for diabetes called GEMS-Insulin, announced today it has raised $6.4 million in a Series A financing. Release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.